Condition (MeSH)
Disseminated Intravascular Coagulation
ClinicalTrials.gov lists 40 trials for Disseminated Intravascular Coagulation or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
40 of the 40 trials are tagged with Disseminated Intravascular Coagulation itself; the rest are tagged with a narrower condition beneath it.
When did Disseminated Intravascular Coagulation trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 3 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 6 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 3 |
| 2015 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Disseminated Intravascular Coagulation trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 2 |
| Not applicable | 5 |
| Observational | 22 |
How many Disseminated Intravascular Coagulation trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 23 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Disseminated Intravascular Coagulation trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 4 |
| Kyowa Kirin Co., Ltd. | 3 |
| Artisan Pharma, Inc. | 1 |
| Asahi Kasei Therapeutics Corporation | 1 |
Which drugs are being tested for Disseminated Intravascular Coagulation? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| KW-3357 | 4 |
| ART-123 | 2 |
| Fibrinogen Concentrate | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| EC Aspirin | 1 |
| BLOOD SAMPLES | 1 |
| NaCl 0.9% NS | 1 |
| Prothrombin Complex Concentrates | 1 |
| OctaplasLG | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Disseminated Intravascular Coagulation trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Haemorrhage | 7 | 1 |
| Catheter site haemorrhage | 5 | 1 |
| Puncture site haemorrhage | 4 | 1 |
| Tracheal haemorrhage | 4 | 1 |
| Epistaxis | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Disseminated Intravascular Coagulation? (114)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A novel description of AT deficiency in hospitalized COVID-19 patients. | European review for medical and pharmacological sciences | 2025 | Yes |
| Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial. | Trials | 2024 | Yes |
| Rotational Thromboelastometry and Clot Waveform Analysis as Point-of-Care Tests for Diagnosis of Disseminated Intravascular Coagulation in Critically Ill Children in Thailand. | Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies | 2024 | Yes |
| Comparison of five different disseminated intravascular coagulation criteria in predicting mortality in patients with sepsis. | PloS one | 2024 | Yes |
| Prevalence and risk factors of disseminated intravascular coagulation in childhood acute lymphoblastic leukemia. | Pediatric research | 2023 | Yes |
Showing 5 of 114 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.